Alternative donor transplantation in acute myeloid leukemia: which source and when?
OBJECTIVE
Acute myeloid leukemia is a heterogeneous disease with a prognosis determined mostly by the leukemic karyotype. Allogeneic transplant in first remission is offered to patients with intermediate- and poor-risk cytogenetics. Only the minority of patients, however, have a matched sibling donor.


RESULTS
Matched unrelated, genetically haploidentical and umbilical cord blood have been increasingly used. Pros and cons of each procedure are discussed, and whenever available, comparisons are made.


CONCLUSIONS
With the progress made in supportive care and prophylaxis of graft-versus-host disease, significant improvement in results of transplant from alternative donors has enabled its increasing use in specific disease stages. The recommended transplant for a given patient and the timing of transplant are discussed.
Zuckerman
Tsila
T
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. t_zuckerman@rambam.health.gov.il
Rowe
Jacob M
JM
D000208:Acute Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D007951:Leukemia, Myeloid / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D014019:Tissue Donors; D016896:Treatment Outcome